Published in Am J Pathol on November 30, 2009
Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS One (2013) 0.89
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol Cancer (2017) 0.75
mRNA-expression of ERα, ERβ, and PR in clonal stem cell cultures obtained from human endometrial biopsies. ScientificWorldJournal (2011) 0.75
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
Applying the principles of stem-cell biology to cancer. Nat Rev Cancer (2003) 8.95
MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell (2009) 8.14
Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer (2008) 3.56
Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium. Biol Reprod (2009) 2.34
MicroRNA-regulated pathways associated with endometriosis. Mol Endocrinol (2008) 2.16
Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology (2008) 1.68
Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther (2006) 1.48
Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene (2002) 1.46
Hormone and growth factor signaling in endometrial renewal: role of stem/progenitor cells. Mol Cell Endocrinol (2008) 1.38
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res (2007) 1.35
Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial carcinoma. J Pathol (2008) 1.29
Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer (1999) 1.26
Oct-4 expression in human endometrium. Mol Hum Reprod (2006) 1.26
Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta (2005) 1.22
Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development. Oncogene (2006) 1.15
Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle (2007) 1.04
The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecol Oncol (2005) 1.03
Endometrial cancer side-population cells show prominent migration and have a potential to differentiate into the mesenchymal cell lineage. Am J Pathol (2009) 0.97
Prognostic significance of syndecan-1 expression in human endometrial cancer. Ann Oncol (2005) 0.88